Guggenheim raised the firm’s price target on Cybin (CYBN) to $48 from $39 and keeps a Buy rating on the shares. Noting that the company’s Phase 3 program for CYB003 in adjunctive MDD is advancing as planned, the firm says it expects Cybin to have “a strong 2026 performance.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYBN:
- Cybin Secures $175 Million in Direct Offering to Advance Clinical Programs
- Psychedelic: Clearmind reports results from first cohort in AUD trial
- Cybin price target lowered to $45 from $70 at Canaccord
- Cybin Inc.: Strategic Positioning and Financial Strength Bolster Buy Rating
- Cybin price target lowered to $55 from $150 at H.C. Wainwright